Search

Your search keyword '"Riemekasten G"' showing total 1,119 results

Search Constraints

Start Over You searched for: "Riemekasten G" Remove constraint "Riemekasten G" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
1,119 results on '"Riemekasten G"'

Search Results

1. [Update on systemic sclerosis].

3. POS0211 PAH TREATMENT AT TIME OF DIAGNOSIS IS ASSOCIATED WITH IMPROVED SURVIVAL REGARDLESS OF HEMODYNAMIC THRESHOLDS AND RISK STRATIFICATION - A EUSTAR ANALYSIS

4. AB1196 BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN SUBJECTS WITH ILD IN A PHASE 2 STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF MT-7117 IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS

5. POS0832 IMMUNOSUPPRESSION VERSUS COMBINATION OF IMMUNOSUPPRESSION AND ORAL GLUCOCORTICOIDS FOR SKIN FIBROSIS IN EARLY DIFFUSE SYSTEMIC SCLEROSIS PATIENTS. A TARGET TRIAL EMULATION STUDY FROM THE EUSTAR DATABASE

6. OP0013 ANTI-Ro/SSA ANTIBODIES ARE PREDICTIVE OF A MORE SEVERE LUNG INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS: A STUDY FROM THE EUSTAR HDATABASE

7. [Interdisciplinary centers for autoimmune diseases in Germany].

9. Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis.

10. Metabolomic signature identifies HDL and apolipoproteins as potential biomarker for systemic sclerosis with interstitial lung disease.

11. Inflammatory tissue priming: novel insights and therapeutic opportunities for inflammatory rheumatic diseases.

12. The Global Evolution and Impact of Systems Biology and Artificial Intelligence in Stem Cell Research and Therapeutics Development: A Scoping Review.

13. [Epidemiological data and medical care situation of patients with chronic inflammatory diseases in Germany : Real-world evidence on prevalence, disease combinations, care].

14. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research

15. Recommendations for defining giant cell arteritis fast-track clinics. English version.

16. Low-dose interleukin-2 therapy: a promising targeted therapeutic approach for systemic lupus erythematosus.

18. OP0238 IMMUNOSUPPRESSION WITH TARGETED DMARDS REDUCES MORBIDITY AND MORTALITY IN PRE-CAPILLARY PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: A EUSTAR ANALYSIS

19. POS0150 AUTOANTIBODIES AGAINST FIBROBLAST GROWTH FACTOR (FGF-2), PLACENTAL GROWTH FACTOR (PLGF) AND BETA-ADRENERGIC RECEPTOR 1 (ADRB1) IN AN ALTERED NETWORK OF AUTOANTIBODIES IN SYSTEMIC SCLEROSIS

21. POS0121 COMPARISON OF FOUR RISK STRATIFICATION MODELS FOR PREDICTION OF MORTALITY IN SSc-PAH IN THE EUSTAR COHORT

24. [Immune-mediated inflammatory diseases in Germany : A cross-sectional analysis of comorbidities and pharmacotherapy].

25. Intensive receptor blockade and plasma exchange to treat refractory scleroderma renal crisis in patients with agonistic autoantibodies targeting the angiotensin II type 1 and endothelin-1 type A receptors.

26. Fighting Post-COVID and ME/CFS – development of curative therapies

32. Impact of systemic sclerosis-associated interstitial lung disease with and without pulmonary hypertension on survival in over 5,000 patients

33. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis.

34. Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?

35. Autoantibodies against the chemokine receptor 3 predict cardiovascular risk.

36. Vasoregulatory Autoantibodies and Clinical Outcome After Ischemic Stroke-PROSCIS-B.

37. Regulatory T cells inhibit autoantigen-specific CD4 + T cell responses in lupus-prone NZB/W F1 mice.

38. Understanding, diagnosing, and treating Myalgic encephalomyelitis/chronic fatigue syndrome - State of the art: Report of the 2nd international meeting at the Charité Fatigue Center.

39. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort

40. Cross-sectional analysis reveals autoantibody signatures associated with COVID-19 severity.

41. S11.3 Low-dose interleukin-2 therapy in active systemic lupus erythematosus (lupil-2): a multi-center, double-blind, randomized and placebo-controlled phase 2 trial

43. Cohort enrichment strategies for progressive interstitial lung disease in systemic sclerosis from EUSTAR

44. Progressive interstitial lung disease is frequent also in late disease stages in systemic sclerosis patients from EUSTAR

45. Risk stratification approaches perform differently in SSc-associated PAH in EUSTAR

46. Therapy satisfaction and health literacy are key factors to improve medication adherence in systemic sclerosis.

47. POS0140 PREDICTING OUTCOMES IN SYSTEMIC SCLEROSIS: STRATIFICATION BY AUTO-ANTIBODIES OUTPERFORMS CUTANEOUS SUBSETTING IN THE EUSTAR COHORT

48. POS0914 LATE SKIN FIBROSIS IN SYSTEMIC SCLEROSIS: A STUDY FROM THE EUSTAR COHORT

Catalog

Books, media, physical & digital resources